

**AESKULISA ASCA-G**

*Ref 3508*







Product Ref.	3508
Product Desc.	ASCA-G
Manual Rev. No.	003 : 2013-10-10

# Instruction Manual

## Table of Contents

---

1	Intended Use .....	1
2	Clinical Application and Principle of the Assay .....	1
3	Kit Contents .....	2
4	Storage and Shelf Life .....	2
5	Precautions of Use.....	3
6	Sample Collection, Handling and Storage.....	4
7	Assay Procedure .....	4
8	Quantitative and Qualitative Interpretation .....	7
9	Technical Data.....	8
10	Performance Data.....	8
11	Literature .....	10





Product Ref.	3508
Product Desc.	ASCA-G
Manual Rev. No.	003 : 2013-10-10

## 1 Intended Use

**AESKULISA ASCA-G** is a solid phase enzyme immunoassay (ELISA) employing highly purified mannan for the quantitative and qualitative detection of IgG anti-Saccharomyces cerevisiae antibodies (ASCA) in human serum. ASCA recognize specific mannan, a component of the outer cell wall of yeast. The assay is highly specific and sensitive for Crohn`s disease.

## 2 Clinical Application and Principle of the Assay

Crohn`s disease is one of the two major Inflammatory Bowel Diseases (IBD). IBD is an umbrella term, that covers both primary disorders causing inflammation or ulceration in the small and large intestine, Crohn`s disease and ulcerative colitis. Crohn`s disease affects both, the small bowel and the colon, unlike ulcerative colitis which is restricted to the colon only. The etiology is not revealed yet, although a genetic and infectious background for the disease is under discussion. Colonoscopy and ileoscopy are the established tools of diagnosis, no serology was available so far. Though Crohn`s disease and ulcerative colitis share several symptoms the course of the diseases, its complications and its management are different, especially when it comes down to surgery. Consequently the differential diagnosis of both diseases is crucial prior to treatment. Aggravating, about 5-10% of the patients can not be distinguished clearly by existing available diagnostic methodologies and are referred to as indeterminate colitis.

ASCA have been found to be specific markers for Crohn`s disease. They have been reported for these patients with a frequency of 68%. The identification of the target antigen mannan, a mannose-rich carbohydrate antigen of the outer cell wall of yeast, enabled the detection of ASCA by enzyme immunoassay.

Being the first available highly specific serological marker, ASCA may become an important tool for the difficult task of diagnosing IBD. Moreover its high positive predictive value offers the only possibility of a convenient and reliable screening and monitoring of risk groups..

### Principle of the test

Serum samples diluted 1:101 are incubated in the microplates coated with the specific antigen. Patient`s antibodies, if present in the specimen, bind to the antigen. The unbound fraction is washed off in the following step. Afterwards anti-human immunoglobulins conjugated to horseradish peroxidase (conjugate) are incubated and react with the antigen-antibody complex of the samples in the microplates. Unbound conjugate is washed off in the following step. Addition of TMB-substrate generates an enzymatic colorimetric (blue) reaction, which is stopped by diluted acid (color changes to yellow). The intensity of color formation from the chromogen is a function of the amount of conjugate bound to the antigen-antibody complex and this is proportional to the initial concentration of the respective antibodies in the patient sample.

### 3 Kit Contents

<b>TO BE RECONSTITUTED</b>				
Item	Quantity	Cap color	Solution color	Description / Contents
Sample Buffer (5x)	1 x 20ml	White	Yellow	5 x concentrated Tris, sodium chloride (NaCl), bovine serum albumin (BSA), sodium azide < 0.1% (preservative)
Wash Buffer (50x)	1 x 20ml	White	Green	50 x concentrated Tris, NaCl, Tween 20, sodium azide < 0.1% (preservative)
<b>READY TO USE</b>				
Item	Quantity	Cap color	Solution color	Description / Contents
Negative Control	1 x 1.5ml	Green	Colorless	Human serum (diluted), bovine serum albumin (BSA), sodium azide < 0.1% (preservative)
Positive Control	1 x 1.5ml	Red	Yellow	Human serum (diluted), bovine serum albumin (BSA), sodium azide < 0.1% (preservative)
Cut-off Calibrator	1 x 1.5ml	Blue	Yellow	Human serum (diluted), bovine serum albumin (BSA), sodium azide < 0.1% (preservative)
Calibrators	6 x 1.5ml	White	Yellow *	Concentration of each calibrator: 0, 3, 10, 30, 100, 300 U/ml. Human serum (diluted), bovine serum albumin (BSA), sodium azide < 0.1% (preservative)
Conjugate, IgG	1 x 15ml	Blue	Blue	Anti-human immunoglobulins conjugated to horseradish peroxidase, bovine serum albumin (BSA)
TMB Substrate	1 x 15ml	Black	Colorless	Stabilized tetramethylbenzidine and hydrogen peroxide (TMB/H <sub>2</sub> O <sub>2</sub> )
Stop Solution	1 x 15ml	White	Colorless	1M Hydrochloric Acid
Microtiter plate	12 x 8 well strips	N/A	N/A	With breakaway microwells. Refer to paragraph 1 for coating.
* Color increasing with concentration				
<b>MATERIALS REQUIRED, BUT NOT PROVIDED</b>				
Microtiter plate reader 450 nm reading filter and recommended 620 nm reference filter (600-690 nm). Glass ware (cylinder 100-1000ml), test tubes for dilutions. Vortex mixer, precision pipettes (10, 100, 200, 500, 1000 µl) or adjustable multipipette (100-1000µl). Microplate washing device (300 µl repeating or multichannel pipette or automated system), adsorbent paper. Our tests are designed to be used with purified water according to the definition of the United States Pharmacopeia (USP 26 - NF 21) and the European Pharmacopeia (Eur.Ph. 4th ed.).				

### 4 Storage and Shelf Life

Store all reagents and the microplate at 2-8°C/35-46°F, in their original containers. Once prepared, reconstituted solutions are stable at 4°C/39°F for at least 1 month. Reagents and the microplate shall be used within the expiry date indicated on each component, only. Avoid intense exposure of TMB solution to light. Store microplates in designated foil, including the desiccant, and seal tightly.



Product Ref.	3508
Product Desc.	ASCA-G
Manual Rev. No.	003 : 2013-10-10

## 5 Precautions of Use

### 5.1 Health hazard data

**THIS PRODUCT IS FOR IN VITRO DIAGNOSTIC USE ONLY.** Thus, only staff trained and specially advised in methods of in vitro diagnostics may perform the kit. Although this product is not considered particularly toxic or dangerous in conditions of the intended use, refer to the following for maximum safety:

#### ***Recommendations and precautions***

This kit contains potentially hazardous components. Though kit reagents are not classified being irritant to eyes and skin we recommend to avoid contact with eyes and skin and wear disposable gloves.

**WARNING !** Calibrators, Controls and Buffers contain sodium azide ( $\text{NaN}_3$ ) as a preservative.  $\text{NaN}_3$  may be toxic if ingested or adsorbed by skin or eyes.  $\text{NaN}_3$  may react with lead and copper plumbing to form highly explosive metal azides. On disposal, flush with a large volume of water to prevent azide build-up. Please refer to decontamination procedures as outlined by CDC or other local/national guidelines.

**Do not smoke, eat or drink when manipulating the kit. Do not pipette by mouth.**

All human source material used for some reagents of this kit (controls, standards e.g.) has been tested by approved methods and found negative for HbsAg, Hepatitis C and HIV 1. However, no test can guarantee the absence of viral agents in such material completely. Thus handle kit controls, standards and patient samples as if capable of transmitting infectious diseases and according to national requirements.

The kit contains material of animal origin as stated in the table of contents, handle according to national requirements.

### 5.2 General directions for use

In case that the product information, including the labeling, is defective or incorrect please contact the manufacturer or the supplier of the test kit.

Do not mix or substitute Controls, Calibrators, Conjugates or microplates from different lot numbers. This may lead to variations in the results.

Allow all components to reach room temperature (20-32°C/68-89.6°F) before use, mix well and follow the recommended incubation scheme for an optimum performance of the test.

**Incubation: We recommend test performance at 30°C/86°F for automated systems.**

Never expose components to higher temperature than 37°C/ 98.6°F.

Always pipette substrate solution with brand new tips only. Protect this reagent from light. Never pipette conjugate with tips used with other reagents prior.

**A definite clinical diagnosis should not be based on the results of the performed test only, but should be made by the physician after all clinical and laboratory findings have been evaluated. The diagnosis is to be verified using different diagnostic methods.**



## 6 Sample Collection, Handling and Storage

---

Use preferentially freshly collected serum samples. Blood withdrawal must follow national requirements. Do not use icteric, lipemic, hemolysed or bacterially contaminated samples. Sera with particles should be cleared by low speed centrifugation (<1000 x g). Blood samples should be collected in clean, dry and empty tubes.

After separation, the serum samples should be used during the first 8h, respectively stored tightly closed at 2-8°C/35-46°F up to 48h, or frozen at -20°C/-4°F for longer periods

## 7 Assay Procedure

---

### 7.1 Preparations prior to starting

Dilute concentrated reagents:

Dilute the concentrated sample buffer 1:5 with distilled water (e.g. 20 ml plus 80 ml).

Dilute the concentrated wash buffer 1:50 with distilled water (e.g. 20 ml plus 980 ml).

To avoid mistakes we suggest to mark the cap of the different calibrators.

#### **Samples:**

Dilute serum samples 1:101 with sample buffer (1x)

e.g. 1000 µl sample buffer (1x) + 10 µl serum. Mix well !

#### **Washing:**

Prepare 20 ml of diluted wash buffer (1x) per 8 wells or 200 ml for 96 wells

e.g. 4 ml concentrate plus 196 ml distilled water.

#### **Automated washing:**

Consider excess volumes required for setting up the instrument and dead volume of robot pipette.

#### **Manual washing:**

Discard liquid from wells by inverting the plate. Knock the microwell frame with wells downside vigorously on clean adsorbent paper. Pipette 300 µl of diluted wash buffer into each well, wait for 20 seconds. Repeat the whole procedure twice again.

#### **Microplates:**

Calculate the number of wells required for the test. Remove unused wells from the frame, replace and store in the provided plastic bag, together with desiccant, seal tightly (2-8°C/35-46°F).

## 7.2 Pipetting Scheme

We suggest pipetting calibrators, controls and samples as follows:

For <i>QUANTITATIVE</i> interpretation					For <i>QUALITATIVE</i> interpretation				
	1	2	3	4...		1	2	3	4...
<b>A</b>	Cal A	Cal E	P1		<b>A</b>	NC	P2		
<b>B</b>	Cal A	Cal E	P1		<b>B</b>	NC	P2		
<b>C</b>	Cal B	Cal F	P2		<b>C</b>	CC	P3		
<b>D</b>	Cal B	Cal F	P2		<b>D</b>	CC	P3		
<b>E</b>	Cal C	PC	P3		<b>E</b>	PC	...		
<b>F</b>	Cal C	PC	P3		<b>F</b>	PC	...		
<b>G</b>	Cal D	NC	...		<b>G</b>	P1	...		
<b>H</b>	Cal D	NC	...		<b>H</b>	P1	...		

CalA: calibrator A

CalB: calibrator B

CalC: calibrator C

CalD: calibrator D

CalE: calibrator E

CalF: calibrator F

PC: positive control

NC: negative control




CC: cut-off calibrator

P1: patient 1

P2: patient 2

P3: patient 3

## 7.3 Test Steps

Step	Description
1.	Ensure preparations from step 7.1 above have been carried out prior to pipetting.
2.	Use the following steps in accordance with quantitative/ qualitative interpretation results desired:
<b>CONTROLS &amp; SAMPLES</b>	
3.	 <p>Pipette into the designated wells as described in chapter 7.2 above, 100 µl of either:</p> <ol style="list-style-type: none"> <li>Calibrators (CAL.A to CAL.F) for <i>QUANTITATIVE</i> or</li> <li>Cut-off Calibrator (CC) for <i>QUALITATIVE</i> interp.</li> </ol> <p>and 100 µl of each of the following:</p> <ul style="list-style-type: none"> <li>Negative control (NC) and Positive control (PC), and</li> <li>Patients diluted serum (P1, P2...)</li> </ul>
4.	 <p>Incubate for 30 minutes at 20-32°C/68-89.6°F.</p>
5.	 <p>Wash 3x with 300 µl washing buffer (diluted 1:50).</p>





Product Ref.	3508
Product Desc.	ASCA-G
Manual Rev. No.	003 : 2013-10-10

### CONJUGATE


6.

CONJ



Pipette 100 µl conjugate into each well.


7.



Incubate for 30 minutes at 20-32°C/68-89.6°F.

8.

WASHB



Wash 3x with 300 µl washing buffer (diluted 1:50).

### SUBSTRATE

9.

SUB



Pipette 100 µl TMB substrate into each well.

10.




Incubate for 30 minutes at 20-32°C/68-89.6°F, protected from intense light.

### STOP

11.

STOP



Pipette 100 µl stop solution into each well, using the same order as pipetting the substrate.

12.




Incubate 5 minutes minimum.

13.

Agitate plate carefully for 5 sec.

14.



Read absorbance at 450 nm (recommended 450/620 nm) within 30 minutes.



## 8 Quantitative and Qualitative Interpretation

For **quantitative interpretation** establish the standard curve by plotting the **optical density (OD) of each calibrator (y-axis)** with respect to the corresponding concentration values in U/ml (x-axis). For best results we recommend log/lin coordinates and 4-Parameter Fit. From the OD of each sample, read the corresponding antibody concentrations expressed in U/ml.

Normal Range	Equivocal Range	Positive Results
< 12 U/ml	12 - 18 U/ml	>18 U/ml

### Example of a standard curve

**Do NOT use this example for interpreting patient's result**

Calibrators IgG	OD 450/620 nm	CV % (Variation)
0 U/ml	0.032	2.8
3 U/ml	0.152	2.6
10 U/ml	0.281	1.2
30 U/ml	0.646	2.4
100 U/ml	1.214	1.7
300 U/ml	2.104	1.6

### Example of calculation

Patient	Replicate (OD)	Mean (OD)	Result (U/ml)
P 01	0.904/0.937	0.921	58.3
P 02	0.564/0.551	0.558	25.9

Samples above the highest calibrator range should be reported as >Max. They should be diluted as appropriate and re-assayed. Samples below calibrator range should be reported as < Min.

For lot specific data, see enclosed quality control leaflet. Medical laboratories might perform an in-house quality control by using own controls and/or internal pooled sera, as foreseen by national regulations.

Each laboratory should establish its own normal range based upon its own techniques, controls, equipment and patient population according to their own established procedures.

In case that the values of the controls do not meet the criteria the test is invalid and has to be repeated.

The following technical issues should be verified: Expiration dates of (prepared) reagents, storage conditions, pipettes, devices, photometer, incubation conditions and washing methods.

If the items tested show aberrant values or any kind of deviation or that the validation criteria are not met without explicable cause please contact the manufacturer or the supplier of the test kit.

For **qualitative interpretation** read the optical density of the cut-off calibrator and the patient samples. Compare patient's OD with the OD of the cut-off calibrator. For qualitative interpretation we recommend to consider sera within a range of 20% around the cut-off value as equivocal. All samples with higher ODs are considered positive, samples with lower ODs are considered negative.

<b>Negative:</b>	OD patient	<	0.8 x OD cut-off
<b>Equivocal:</b>	0.8 x OD cut-off	≤	OD patient ≤ 1.2 x OD cut-off
<b>Positive:</b>	OD patient	>	1.2 x OD cut-off

## 9 Technical Data

Sample material:	serum
Sample volume:	10 µl of sample diluted 1:101 with 1x sample buffer
Total incubation time:	90 minutes at 20-32°C/68-89.6°F
Calibration range:	0-300 U/ml
Analytical sensitivity:	1.0 U/ml
Storage:	at 2-8°C/35-46°F use original vials only.
Number of determinations:	96 tests

## 10 Performance Data

### 10.1 Analytical sensitivity

Testing sample buffer 30 times on AESKULISA ASCA-G gave an analytical sensitivity of 1.0 U/ml.

### 10.2 Clinical Evaluation

The microplates are coated with highly purified mannan from *S. cerevisiae*. For determination of sensitivity and specificity 271 sera suffering from Crohns disease, Ulcerative colitis and several other diseases have been tested on the AESKULISA ASCA-G and a predicate device. The result as a comparison to the predicate device are shown in the table below.

Disease	# Tested	# positive AESKU	% positive AESKU
Crohns Disease	103	81	78.6
Ulcerative Colitis	59	9	15.3
Healthy donors	50	3	6.0
Celiac Disease	30	5	16.7
Systemic Lupus Erythematosus	10	1	10.0
Wegeners Granulomatosis	2	0	0
Sjögrens Syndrome	4	2	50.0
Reactive Arthritis	11	1	9.1
Mixed Connective Tissue disease	1	0	0
Chronic Arthritis	1	0	0



### 10.3 Method Comparison

		other ASCA G assay		
		Pos	Neg	Total
AESKULISA ASCA-G	Pos	74	28	102
	Neg	10	159	169
	Total	84	187	271

pos. agreement: 88.1 % (74/84)  
 neg. agreement: 85.0 % (159/187)  
 total agreement: 86.0 % (233/271)

Be advised that the agreement refers to the comparison of the AESKULISA ASCA-G results to that of another ASCA G kit. There was no attempt to correlate the assay results with the disease presence or absence. No judgement can be made on the comparisons accuracy to predict disease.

### 10.4 Linearity

Chosen sera have been tested with this kit and found to dilute linearly. However, due to the heterogeneous nature of human autoantibodies there might be samples that do not follow this rule.

Sample No.	Dilution Factor	Measured (U/ml)	Expected (U/ml)	Recovery (%) 90-110%
1	1 / 100	275.1	305.4	90.1
	1 / 200	139.6	152.7	91.4
	1 / 400	82.5	76.4	108.1
	1 / 800	41.1	38.2	107.7
2	1 / 100	109.7	106.0	103.5
	1 / 200	49.3	53.0	93.1
	1 / 400	26.9	26.5	101.5
	1 / 800	13.7	13.3	103.3

### 10.5 Precision

To determine the precision of the assay, the variability (intra and inter-assay) was assessed by examining its reproducibility on three serum samples selected to represent a range over the standard curve. (n=18). The accepted range for CV is 10%. (n=24 / 18)

Intra-assay		
Sample No.	Mean (U/ml)	CV (%)
1	16.4	3.9
2	41.0	9.8
3	74.2	3.1

Inter-assay		
Sample No.	Mean (U/ml)	CV (%)
1	15.5	5.5
2	36.1	5.8
3	69.8	3.9

### 10.6 Calibration

Due to the lack of international reference calibration AESKULISA ASCA-G is calibrated in arbitrary units (U/ml).



## 11 Literature

**1.Seibold F, Stich O, Hufnagel R, Kamil S, Scheurlen M (2001).**

*Anti-Saccharomyces cerevisiae antibodies in inflammatory bowel disease: a family study.*

Scand J Gastroenterol 36: 196-201.

**2.Sendid B, Colombel JF, Jacquinot PM et al. (1996).**

*Specific antibody response to pligomannosidic epitopes in Crohn`s disease.*

Clin Diagn Lab Immunol 3: 219-226.

**3.Giaffer MH, Clark A, Holdsworth CD (1992).**

*Antibodies to Saccharomyces cerevisiae in patients with Crohn`s disease and their possible pathogenic importance.*

Gut 33: 1071-1075.

**4.Bernstein CN, Blanchard JC, Rawsthorne P and Wadja A (1999).**

*Epidemiology of Crohn`s disease in a central canadian province: a population-based study.*

Am. J. Epidemiol. 149(10): 916-924.

**5.Glas J, Torok HP, Vilsmaier F, Herbinger KH, Hoelscher M, Folwaczny C (2002)**

*Anti-saccharomyces cerevisiae antibodies in patients with inflammatory bowel disease and their first-degree relatives: potential clinical value.*

Digestion. 66(3):173-177.

**6.Peters M, Joossens S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P (2001)**

*Diagnostic value of Anti-Saccharomyces Cervisiae and antineutrophil cytoplasmatic autoanti bodies in inflammatory bowel disease.*

Am. J. Gastroenterol. 96: 730-734

**7.Sandborn WJ. (2004)**

*Serologic markers in inflammatory bowel disease: state of the art.*

Rev. Gastroenterol. Disord. 4(4):167-74

**8.Rutgeerts P and Vermeire S (1998)**

*Clinical value of the detection of antibodies in the serum for diagnosis and treatment of inflamm- atory bowel disease.*

Gastroenterol. 115: 1006-1022

**9.Klebl FH, Bataille F, Hofstädter F, Herfarth H, Schölmerich J, Rogler G (2004)**

*Optimising the diagnostic value of Anti-Saccharomyces Cerevisiae-antibodies (ASCA) in Crohn`s disease.*

Int. J. Colorectal Dis. 19: 319-24

**10.Lawrance IC, Murray K, Hall A, Sung JJ, Leong R. (2004)**

*A prospective comparative study of ASCA and pANCA in Chinese and Caucasian IBD patients.*

Am. J. Gastroenterol. 99: 2186-94

**11.Damoiseaux JG, Bouten B, Linders AM, Austen J, Roozendaal C, Russel MG, Forget PP,Tervaert JW. (2002)**

*Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies for inflammatory bowel disease: high prevalence in patients with celiac disease.*

J. Clin. Immunol. 22: 281-87

**12.Muratori P, Muratori L, Guidi M, Maccariello S, Pappas G, Ferrari R, Gionchetti P, Campieri M, Bianchi FB. (2003)**

*Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases.*





















Clin.Exp.Immunol. 132: 473 - 476

**13.Sutton CL, Yang H, Li Z, Rotter JI, Targan SR, and Braun J. (2003)**

*Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and un-affected relatives of patients with Crohn`s disease.*

Gut 46: 58 - 63.



	- Diagnosi in vitro	- For in vitro diagnostic use
	- Pour diagnostic in vitro	- Para uso diagnóstico in vitro
	- In Vitro Diagnostikum	- In Vitro Διαγνωστικό μέσο
	- Para uso Diagnóstico in vitro	
	° Numero d'ordine	° Catalogue number
	° Référence Catalogue	° Numéro de catálogo
	° Bestellnummer	° Αριθμός παραγγελίας
	° Número de catálogo	
	° Descrizione lotto	° Lot
	° Lot	° Lote
	° Chargen Bezeichnung	° Χαρακτηρισμός παρτίδας
	° Lote	
	° Conformità europea	° EC Declaration of Conformity
	° Déclaration CE de Conformité	° Declaración CE de Conformidad
	° Europäische Konformität	° Ευρωπαϊκή συμφωνία
	° Déclaracão CE de Conformidade	
	° 96 determinazioni	° 96 tests
	° 96 tests	° 96 pruebas
	° 96 Bestimmungen	° 96 προσδιορισμοί
	° 96 Testes	
	° Rispettare le istruzioni per l'uso	° See instructions for use
	° Voir les instructions d'utilisation	° Ver las instrucciones de uso
	° Gebrauchsanweisung beachten	° Λάβετε υπόψη τις οδηγίες χρήσης
	° Ver as instruções de uso	
	° Da utilizarsi entro	° Use by
	° Utilise avant le	° Utilizar antes de
	° Verwendbar bis	° Χρήση μέχρι
	° Utilizar antes de	
	° Conservare a 2-8°C	° Store at 2-8°C (35-46°F)
	° Conserver à 2-8°C	° Conservar a 2-8°C
	° Lagerung bei 2-8°C	° Φυλάσσεται στους 2-8°C
	° Conservar entre 2-8°C	
	° Prodotto da	° Manufactured by
	° Fabriqué par	° Fabricado por
	° Hergestellt von	° Κατασκευάζεται από
	° Fabricado por	
	° Calibratore cut-off	° Cut off Calibrator
	° Etalon Seuil	° Calibrador de cut-off
	° Grenzwert Kalibrator	° Οριακός ορός Αντιδραστήριο βαθμονόμησης
	° Calibrador de cut-off	
	° Controllo positivo	° Positive Control
	° Contrôle Positif	° Control Positivo
	° Positiv Kontrolle	° Θετικός ορός ελέγχου
	° Controllo positivo	
	° Controllo negativo	° Negative Control
	° Contrôle Négatif	° Control Negativo
	° Negativ Kontrolle	° Αρνητικός ορός ελέγχου
	° Controllo negativo	
	° Calibratore	° Calibrator
	° Etalon	° Calibrador
	° Kalibrator	° Αντιδραστήριο βαθμονόμησης
	° Calibrador	
	° Recupero	° Recovery
	° Corrélation	° Recuperado
	° Wiederfindung	° Ανάκτηση
	° Recuperação	
	° Coniugato	° Conjugate
	° Conjugé	° Conjugado
	° Konjugat	° Σύζευγμα
	° Conjugado	
	° Micropiastra rivestita	° Coated microtiter plate
	° Microplaque sensibilisée	° Microplaca sensibilizada
	° Beschichtete Mikrotiterplatte	° Επικαλυμμένη μικροπλάκα
	° Microplaca revestida	
	° Tampone di lavaggio	° Wash buffer
	° Tampon de Lavage	° Solución de lavado
	° Waschpuffer	° Ρυθμιστικό διάλυμα πλύσης
	° Solução de lavagem	
	° Tampone substrato	° Substrate buffer
	° Substrat	° Tampón sustrato
	° Substratpuffer	° Ρυθμιστικό διάλυμα υποστρώματος
	° Substrato	
	° Reagente bloccante	° Stop solution
	° Solution d'Arrêt	° Solución de parada
	° Stopreagenz	° Αντιδραστήριο διακοπής αντίδρασης
	° Solução de paragem	
	° Tampone campione	° Sample buffer
	° Tampon Echantillons	° Tampón Muestras
	° Probenpuffer	° Ρυθμιστικό διάλυμα δειγμάτων
	° Diluente de amostra	